Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Debio 2512
- Development stage
- Preclinical
- Lead developer
- Debiopharm
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Debio 2512 is a bispecific antibody-drug conjugate (ADC) developed by Debiopharm, utilizing an anti-HER2 x HER3 bispecific antibody platform originally developed by SunRock Biopharma (antibody code: SRB21). The primary mechanism involves concurrently targeting **HER2** and **HER3** receptors, which are members of the epidermal growth factor receptor (EGFR) family overexpressed in several cancer types. By dual targeting, Debio 2512 is designed to address and potentially overcome resistance mechanisms that limit current HER2-targeted therapies. The drug is in preclinical development and aims to exploit antitumor activities through specific delivery of cytotoxic payloads to HER2/HER3-expressing cancer cells.
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on Debio 2512.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Debio 2512.